# Becotatug Vedotin Plus Pucotenlimab for Advanced Biliary Tract Cancer, Phase II

> **NCT07649980** · PHASE2 · NOT_YET_RECRUITING · sponsor: **HuiKai Li** · enrollment: 30 (estimated)

## Conditions studied

- Biliary Tract Cancer (BTC)
- EGFR-positive Advanced Biliary Tract Carcinoma

## Interventions

- **DRUG:** Becotatug Vedotin
- **DRUG:** Pucotenlimab

## Key facts

- **NCT ID:** NCT07649980
- **Lead sponsor:** HuiKai Li
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2029-07-01
- **Final completion:** 2029-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07649980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07649980, "Becotatug Vedotin Plus Pucotenlimab for Advanced Biliary Tract Cancer, Phase II". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07649980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*